PURPOSE
Extranodal extension (ENE) is a key determinant of adjuvant therapy in node-positive oral cavity squamous cell carcinoma (OCSCC). However, conventional nodal staging may not fully capture the quantitative burden of nodal disease. We evaluated whether lymph node ratio (LNR) provides additional prognostic value b...
Anuj Kumar, S. Ghosh-Laskar, Prashasti Sharma et al.· Radiotherapy and Oncology· 0 citations
Background De novo metastatic nasopharyngeal carcinoma (mNPC) carries a poor prognosis with systemic therapy alone. Locoregional radiotherapy (LRRT) improves survival in chemotherapy-responsive patients, but the incremental role of metastasis-directed therapy (MDT) remains undefined. Methods This retrospective cohort i...
S. Ghosh-Laskar, Anuj Kumar, R. Malhotra et al.· Clinical and Translational R...· 0 citations
Background: This retrospective study introduces imaging inner tumor margin patterns (iITMP) and evaluates their correlation with pathological Worst pattern of invasion (WPOI) in oral tongue squamous cell carcinoma (OTSCC). Associations of iITMP with pathological primary tumor category (pT), histologic grade, perineural...
N. Chakrabarty, Tapish Dadlani, A. Mahajan et al.· Cancers· 0 citations
Abstract Cancer care delivery in low- and middle-income settings faces persistent challenges related to increasing disease burden, delayed presentation, and limited healthcare infrastructure. Bihar, India, a predominantly rural and socioeconomically underserved state, lacked dedicated comprehensive tertiary oncology se...
Ravikant Singh, Naresh Gupta, Nishant Kumar et al.· Indian Journal of Medical an...· 0 citations
By identifying low-risk patients within the NCCN high-risk group and high-risk patients within the NCCN low + intermediate-risk group for recurrence, these models may support treatment de-escalation and escalation, respectively, pending prospective multicenter validation.
N. Chakrabarty, S. Rane, U. Sherkhane et al.· Frontiers in Oncology· 1 citation
KRAS-mutant NSCLC is transitioning from historically untargetable disease to a therapeutically actionable subset, and future progress hinges on resistance-directed combinations, biomarker-guided personalization, expansion to non-G12C mutants, and evaluation in earlier disease settings.
A. Kapoor, Bipinesh Sansar, Anuj Gupta et al.· Medical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.